Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and amon...
Enregistré dans:
Auteurs principaux: | Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Kamila T. Akhmetgareeva, Danila O. Lipatov |
---|---|
Format: | article |
Langue: | RU |
Publié: |
IP Habib O.N.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
par: L. V. Bolotina
Publié: (2020) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
par: Xiaozhun Huang, et autres
Publié: (2021) -
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
par: Jie Zhu, et autres
Publié: (2021) -
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
par: Tetsu Tomonari, et autres
Publié: (2021) -
Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo
par: Ching-Hsuan Wu, et autres
Publié: (2022)